What's happened
The UK and US have finalized a medicines partnership allowing British drug exports to avoid US tariffs and increasing NHS drug spending. Critics warn it risks NHS funding and transparency, while supporters highlight potential benefits for patients and the UK economy. The deal's details remain partly secret, raising concerns about oversight.
What's behind the headline?
The UK-US medicines deal represents a strategic move to protect British pharmaceutical exports from US tariffs, potentially saving up to bn annually. However, critics argue that the deal prioritizes industry profits over NHS sustainability, with estimates suggesting it could cost the UK bn annually by 2035. The relaxation of NICE's cost-effectiveness thresholds to -35,000 per quality-adjusted life year signals a shift towards more expensive treatments, raising questions about long-term NHS affordability.
The secrecy surrounding the full deal text fuels suspicion about its true costs and implications. While the government claims it benefits patients by expanding access to innovative drugs, campaigners warn it could lead to higher NHS drug prices and reduced scrutiny. The agreement also signals a broader alignment of regulatory standards, including mutual recognition of medical device approvals, which could streamline access but also diminish independent oversight.
The deal's timing coincides with increased US influence on UK healthcare policy, driven by industry lobbying and geopolitical considerations. The potential resumption of investments by firms like Eli Lilly hinges on the UK adopting more flexible pricing schemes, including outcome-based models for anti-obesity drugs. This underscores a shift towards market-driven healthcare, which may benefit pharmaceutical companies but risks undermining NHS financial stability and equitable access.
What the papers say
The Guardian highlights concerns over NHS funding and transparency, emphasizing critics' fears that the deal favors industry profits at the expense of public health. Politico notes the UK's commitment to increasing pharmaceutical spending to 0.6% of GDP by 2035, framing it as a strategic step to meet US demands and boost the life sciences sector. Reuters reports Eli Lilly's negotiations to resume UK investments contingent on more flexible pricing, illustrating industry pressure for higher drug prices. The articles collectively reveal a complex balance between economic interests, regulatory alignment, and public health priorities, with critics warning that the long-term impact on NHS sustainability remains uncertain.
How we got here
The deal follows years of negotiations influenced by US pressure to reform drug pricing and access. It aims to boost UK pharmaceutical exports and align regulatory standards, including mutual recognition of medical device approvals. The UK also plans to increase its healthcare spending to 0.6% of GDP by 2035, partly to meet these new commitments.
Go deeper
Common question
-
What Does the UK-US Pharma Deal Mean for Healthcare?
The UK and US have recently agreed to recognize each other's medical device approvals and boost pharmaceutical spending, aiming to modernize healthcare and attract investment. This deal raises questions about how it will impact drug prices, innovation, and patient access in both countries. Below, we explore the key aspects of this agreement and what it could mean for the future of healthcare cooperation.
More on these topics
-
Sir Keir Rodney Starmer KCB QC MP is a British politician and former lawyer who has served as Leader of the Labour Party and Leader of the Opposition since 2020. He has been Member of Parliament for Holborn and St Pancras since 2015.
-
The National Institute for Health and Care Excellence is an executive non-departmental public body of the Department of Health in England, which publishes guidelines in four areas: